<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INSULIN ASPART</span><br/>(in'su-lyn)<br/><span class="topboxtradename">NovoLog<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">antidiabetic agent</span>; <span class="classification">insulin</span><br/><b>Prototype: </b>Insulin Injection<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 U/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>A recombinant insulin analog that is more rapidly absorbed than human insulin, with a more rapid onset and shorter duration
         than regular human insulin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Provides better blood glucose control than regular human insulin when given before a meal.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of diabetes mellitus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Systemic allergic reactions; history of allergic reactions to insulin; hypoglycemia; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Fever, hyperthyroidism, surgery or trauma; decreased insulin requirements due to diarrhea, nausea, or vomiting, malabsorption;
         renal or hepatic impairment, hypokalemia; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diabetes</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 0.250.7 units/kg/d injected 510 min before each meal<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li> 				Note: Must give 510 min before a meal. 			</li>
<li>Draw up insulin aspart first when mixing with NPH insulin. Give injection immediately after it is mixed. Do not give NPH mixture
            by IV.
         </li>
<li>Store refrigerated at 2°8° C (36°46° F); may be stored at room temperature, 15°30°
            C (59°86° F) for up to 28 d. Do not expose to excessive heat or sunlight, and do not freeze.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Allergic reactions. <span class="typehead">Endocrine:</span> Hypoglycemia, hypokalemia. <span class="typehead">Skin:</span> Injection site reaction, lipodystrophy, pruritus, rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">oral antidiabetic agents</span>, <span class="classification">ace inhibitors</span>, <b>disopyramide,</b> <b>fluoxetine,</b> <span class="classification">mao inhibitors</span>, <b>propoxyphene,</b> <span class="classification">salicylates</span>, <span class="classification">sulfonamide antibiotics</span>, <b>octreotide</b> may enhance hypoglycemia; <span class="classification">corticosteroids</span>, <b>niacin,</b> <b>danazol,</b> <span class="classification">diuretics</span>, <span class="classification">sympathomimetic agents</span>, <span class="classification">phenothiazines</span>, <span class="classification">thyroid hormones</span>, <span class="classification">estrogens</span>, <span class="classification">progestogens</span>, <b>isoniazid,</b> <b>somatropin</b> my decrease hypoglycemic effects; <span class="classification">beta-blockers</span>, <b>clonidine,</b> <b>lithium,</b> <b>alcohol</b> may either potentiate or weaken effects of insulin; <b>pentamidine</b> may cause hypoglycemia followed by hyperglycemia. <span class="typehead">Herbal:</span> <b>Garlic,</b> <b>ginseng</b> may potentiate hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from SC injection site. <span class="typehead">Onset:</span> 15 min. <span class="typehead">Peak:</span> 4050 min. <span class="typehead">Duration:</span> 35 h. <span class="typehead">Distribution:</span> Low protein binding. <span class="typehead">Metabolism:</span> Metabolized primarily in liver with some metabolism in the kidneys. <span class="typehead">Half-Life:</span> 81 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypoglycemia (see Appendix F). Initial hypoglycemic response begins within 15 min and peaks 4590
            min after injection.
         </li>
<li>Lab tests: Periodically monitor fasting blood glucose and HbA<sub>1C</sub>.
         </li>
<li>Withhold drug and notify physician if patient is hypokalemic.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not inject into areas with redness, swelling, itching, or dimpling.</li>
<li>Ingest some form of sugar (e.g., orange juice, dissolved table sugar, honey) if symptoms of hypoglycemia develop, and seek
            medical assistance.
         </li>
<li>Check blood sugar as prescribed, especially postprandial values; notify physician of fasting blood glucose 120 mg/dL.</li>
<li>Notify the physician of any of the following: Fever, infection, trauma, diarrhea, nausea or vomiting. Dosage adjustment may
            be needed.
         </li>
<li>Do not take any other medication unless approved by the physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>